Skip to Content

Pfizer Ends Prostate Cancer Study Of Sutent

From Associated Press (September 27, 2010)

NEW YORK -- Pfizer Inc. said Monday it has ended a late-stage clinical trial of its cancer drug Sutent, after seeing no survival benefit for patients with castration-resistant prostate cancer.

Sutent is already approved as a treatment for kidney cancer and for tumors of the stomach, esophagus, and bowels that do not respond to other treatment. Pfizer is seeking additional approvals, but has reported two unsuccessful trials in recent weeks. In late August, it said Sutent failed in a late-stage study testing it as a treatment for lung cancer.

Pfizer said it ended the prostate cancer study on the recommendation of an independent data monitoring committee. The study was designed to compare a combination regimen of Sutent and prednisone to prednisone alone. The committee said patients who took the Sutent regimen were not living significantly longer than those on the single drug.

The patients had advanced prostate cancer that had progressed despite treatment with the chemotherapy drug docetaxel.

Separately, Pfizer said it currently has 118 drug programs in clinical development, down from 133 in January. Since then it has started or advanced studies of 25 drugs, and discontinued 31 others. Pfizer said it is awaiting regulatory decisions in the U.S. or Europe on nine drug candidates. Its programs include 26 drugs in late-stage development. Its product candidates include 27 biotech drugs and four potential vaccines.

Some of those drug candidates were acquired when Pfizer bought competitor Wyeth in October 2008. The $68 billion deal made Pfizer the world’s biggest drug maker by revenue, and gave it Wyeth’s biologic drug and consumer and animal health businesses.

Pfizer stock declined 23 cents to close the regular session at $17.17.


Posted: September 2010